Provided by Tiger Trade Technology Pte. Ltd.

CLIMB BIO INC

16.08
-1.7600-9.87%
Post-market: 16.230.1500+0.93%19:50 EDT
Volume:1.39M
Turnover:22.99M
Market Cap:920.75M
PE:-19.26
High:17.80
Open:17.72
Low:16.01
Close:17.84
52wk High:18.33
52wk Low:1.54
Shares:57.26M
Float Shares:41.60M
Volume Ratio:1.26
T/O Rate:3.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8347
EPS(LYR):-0.8974
ROE:-27.10%
ROA:-18.45%
PB:3.84
PE(LYR):-17.92

Loading ...

Wedbush Raises Price Target on Climb Bio to $20 From $17, Keeps Outperform Rating

MT Newswires Live
·
Jul 27

Climb Bio Director Breanna Maurine Celebi Files Initial Beneficial Ownership Statement

Reuters
·
Jul 02

Climb Bio Names Breanna O’reilly to Board After Andrew Levin Resigns

Reuters
·
Jul 02

Climb Bio Price Target Maintained with a $20.00/share by HC Wainwright & Co.

Dow Jones
·
Jun 24

Tango Therapeutics appoints Robert Azelby to board of directors

Reuters
·
Jun 23

BRIEF-Climb Bio - Enters Open Market Sale Agreement With Jefferies - SEC Filing

Reuters
·
Jun 13

Climb Bio enters Jefferies ATM equity distribution agreement for up to $100 million stock sale

Reuters
·
Jun 13

Climb Bio - Enters Open Market Sale Agreement With Jefferies Dated June 12, 2026 - SEC Filing

THOMSON REUTERS
·
Jun 13

Analysts Conflicted on These Healthcare Names: United Therapeutics (UTHR), DENTSPLY SIRONA (XRAY) and Climb Bio (CLYM)

TIPRANKS
·
Jun 12

Climb Bio price target raised to $20 from $19 at BTIG

TIPRANKS
·
Jun 12

Analysts Offer Insights on Healthcare Companies: Schrodinger (SDGR) and Climb Bio (CLYM)

TIPRANKS
·
Jun 12

Climb Bio Is Maintained at Buy by BTIG

Dow Jones
·
Jun 11

Climb Bio reports initial Phase 1b data showing platelet responses for budoprutug in immune thrombocytopenia trial

Reuters
·
Jun 11

Climb Bio - Announces Initial Phase 1B Data for Budoprutug in Immune Thrombocytopenia

THOMSON REUTERS
·
Jun 11

Climb Bio - Enrollment Ongoing in 1000 Mg Cohort With Data Expected by Year-End 2026

THOMSON REUTERS
·
Jun 11

Climb Bio sets 5,216,105-share cap under 2021 equity incentive plan

Reuters
·
Jun 09

Climb Bio initiated with a Buy at Guggenheim

TIPRANKS
·
Jun 08

Guggenheim Initiates Climb Bio at Buy With $35 Price Target

MT Newswires Live
·
Jun 08

Climb Bio Price Target Maintained With a $19.00/Share by BTIG

Dow Jones
·
Jun 08

Analysts Are Bullish on Top Healthcare Stocks: RegenXBio (RGNX), Climb Bio (CLYM)

TIPRANKS
·
Jun 06